Un Audited financial results for the Quarter and Half year ended 30.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical, a subsidiary of Virupaksha Organics, reported unaudited results for Q2 FY26 with net sales of Rs 1,430.23 lakhs (vs Rs 1,400.52 lakhs YoY), marking only modest top-line growth. However, losses widened sharply — loss before tax for the quarter was Rs 643.78 lakhs compared to Rs 277.33 lakhs loss a year ago, and H1 FY26 loss before tax was Rs 1,458.79 lakhs vs Rs 514.05 lakhs last year. The company's total equity is in the negative at Rs (3,667.92) lakhs as of Sept 30, 2025, with total borrowings of roughly Rs 7,283 lakhs. Separately, the board appointed Mr. Prasad Reddy Battinapatla (a Chartered Accountant with ~15 years' experience) as the new CFO effective 07.11.2025, and approved a Postal Ballot notice along with appointment of scrutinizers.
Worsening losses combined with a negative net worth flag serious financial stress for this small-cap pharma, even though revenue is flat-ish. The new CFO appointment is a routine governance update, and the postal ballot hints at an upcoming corporate action shareholders should watch.